Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
USFDA update
Regulatory Filings Classification · 82% confidence The document is a stock exchange disclosure under SEBI Listing Regulations providing an operational update on a USFDA inspection at a contract manufacturing facility. It is not a full report (e.g., Annual or Interim), nor is it a management change, dividend, or capital transaction. It is a general regulatory announcement filed with exchanges. Thus, it falls under Regulatory Filings (RNS).
2026-05-29 English
General Updates
Regulatory Filings Classification · 90% confidence The document is a compliance disclosure sent to stock exchanges under Regulation 30 of SEBI LODR, providing an update on a USFDA inspection and warning letter at the company’s contract manufacturing facility. It is neither a financial report, board change, dividend notice, capital update, nor a meeting proxy. It is a general regulatory announcement/fallback filing. Therefore it falls under Regulatory Filings (RNS).
2026-05-29 English
Annual Secretarial Compliance Report
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report filed under SEBI LODR Regulations. It is an officer-attestation style compliance certificate and does not contain substantive financial statements or serve as a financial report (Annual Report, Interim Report, etc.). It is neither a proxy solicitation, dividend notice nor an earnings release. As it is primarily a regulatory disclosure/compliance filing rather than a full report, it falls under the general “Regulatory Filings” category.
2026-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is clearly a full transcript of an earnings webinar/conference call, including management presentations, moderator instructions, and Q&A exchanges regarding quarterly and annual financial results. It is not a brief earnings release or a simple announcement; it is the complete call transcript. Therefore, it falls under the “Call Transcript” category.
2026-05-27 English
Earnings Call Transcript
Call Transcript Classification · 95% confidence The document is a detailed transcript of an earnings webinar (Q4 & FY2026) held on May 22, 2026, including management presentations, a moderator, Q&A with analysts, and forward-looking statements. It is not the earnings release itself but the full call transcript. This matches the definition of a Call Transcript (CT).
2026-05-27 English
Newspaper Publication
Report Publication Announcement Classification · 90% confidence The document is a letter to the BSE and NSE under SEBI LODR Regulations 30 and 47 notifying that the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been published in newspapers and posted on the company website. It does not itself contain detailed financial statements but encloses copies of the publication. This is an announcement of report publication rather than the report itself.
2026-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.